Bayer's Asundexian Demonstrates Strong Efficacy in Preventing Recurrent Stroke Without Increased Bleeding Risk

Groundbreaking Results from OCEANIC-STROKE Trial

Bayer, the German pharmaceutical giant, has announced compelling results from its Phase III OCEANIC-STROKE study, revealing that its investigational drug, Asundexian, significantly reduces the risk of recurrent ischemic stroke. The findings, presented at the International Stroke Conference 2026 in New Orleans, USA, indicate a 26% reduction in ischemic stroke risk when Asundexian is added to antiplatelet medication, without an increased risk of major bleeding. This outcome marks a significant advancement in the prevention of secondary strokes.

A New Approach to Stroke Prevention

Asundexian operates as an oral Factor XIa inhibitor, targeting a protein in the blood coagulation pathway. Unlike some traditional anticoagulants, this mechanism aims to prevent clot formation with a reduced impact on hemostasis, thereby minimizing bleeding complications. The OCEANIC-STROKE trial enrolled over 12,300 participants globally who had previously experienced a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack (TIA). The consistency of the drug's efficacy was observed across diverse patient subgroups, including variations in age, sex, and the initial cause or severity of stroke.

Safety Profile and Clinical Significance

A critical aspect of the trial's success is Asundexian's favorable safety profile. The study reported no increase in major bleeding, including intracranial bleeding, a common concern with anticoagulant therapies. Bleeding risks for minor bleeding, hemorrhagic stroke, symptomatic intracranial hemorrhage, and fatal bleeding were found to be similar between the Asundexian and placebo groups. This balance of efficacy and safety positions Asundexian as a potentially transformative treatment for patients at high risk of recurrent stroke. According to Dr. Mike Sharma, a principal investigator for OCEANIC-STROKE, 'Asundexian—when combined with standard antiplatelet therapy—helped reduce the chances of having another stroke without increasing the risk of bleeding.' He further noted that 'This is a major advance in our ability to prevent strokes in people at risk of stroke recurrence.'

Regulatory Pathway and Future Outlook

The positive results from OCEANIC-STROKE are a crucial step for Asundexian's journey toward regulatory approval. The drug previously received Fast Track Designation from the U.S. Food and Drug Administration (FDA) in February 2022 for secondary stroke prevention, underscoring its potential to address an unmet medical need. While a separate Phase III trial, OCEANIC-AF, investigating Asundexian for atrial fibrillation, was terminated early due to a lack of efficacy compared to apixaban, the success in the stroke prevention setting provides renewed momentum for Bayer's cardiovascular pipeline. This development offers hope for millions of stroke survivors worldwide who face a substantial risk of recurrence.